Owkin combines life-science and machine learning expertise to make drug development and clinical trial design more targeted and more cost effective. Owkin’s machine learning algorithms create models that predict disease evolution and treatment outcomes. These predictive models are implemented in clinical trials for enhanced analysis, surrogate endpoints, patient stratification, patient selection, and high-value subgroup identification. The impact of this research is faster discovery of better treatments at a lower cost.
Region: North America
Abelian Therapeutics
Nascent biotech company harnessing emerging science on the importance of Glia in brain disease. Abelian Therapeutics was acquired in September 2020.
Pony.ai
Founded in late 2016 by former Baidu Chief Architect James Peng (CEO) and programming legend Tiancheng Lou (CTO), Pony.ai aims to revolutionize the future of transportation by building the safest and most reliable self-driving technology.
An Eight Roads investment. Eight Roads is F-Prime’s sister venture capital investment group, with which F-Prime collaborates on investments outside of the Americas and Europe.
BlackDuck
BlackDuck secures and manages open source software worldwide, eliminating open source security vulnerabilities & license compliance pain. BlackDuck was acquired by Synopsys in 2017.
A Fidelity Ventures investment. Fidelity Ventures was a venture capital investment group affiliated with F-Prime until 2010.
mindSHIFT
mindSHIFT is one of the largest IT outsourcing and cloud services providers. The company has supported our clients with tailored and trusted technology solutions for more than 15 years. From day-to-day IT to major systems modernization, count on mindSHIFT’s technology expertise and personalized customer care for all of your IT needs. mindSHIFT was acquired by Roche Company in 2014.
A Fidelity Ventures investment. Fidelity Ventures was a venture capital investment group affiliated with F-Prime until 2010.
Sana Biotechnology
Sana Biotechnology, Inc. (NASDAQ: SANA) is focused on creating and delivering engineered cells as medicine for patients. We are a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and changes how we approach treating disease.
AvantStay
AvantStay delivers exceptional, unique stays for group travelers. The company has built a tech-enabled millennial hospitality brand to be the new standard for group experience. Unlike typical short-term rentals, Avantstay controls the entire guest experience. This allows the company to ensure the quality of a guest’s stay will be consistent across all homes and to deliver hotel-level comfort in an authentic differentiated setting.
Seyond
Seyond (formerly Innovusion) is a leading developer of image-grade LiDAR sensor systems for level 4+ of the autonomous vehicle market. Its unique combination of range, resolution, hardware accelerated sensor fusion, compact size, ease of integration and cost effectiveness makes its products an ideal choice for the most demanding applications.
Modis Therapeutics
Modis Therapeutics, Inc. was formed in 2016 through a collaboration with academic experts in mitochondrial biology. The company’s lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. Modis Therapeutics is headquartered in Oakland CA, with offices in New York City. Modis was acquired by Zogenix.
b-ONE Ortho
b-ONE Ortho Corp. is an emerging orthopedic technology company dedicated to the development of innovative orthopedic healthcare solutions that restore patient mobility and improve surgical outcomes. Every day we are committed to becoming the most credible choice for orthopedic products worldwide.